enGene Therapeutics (ENGN) Operating Leases (2024 - 2026)

enGene Therapeutics (ENGN) has 3 years of Operating Leases data on file, last reported at $5.7 million in Q3 2026.

• For the quarter ending Q3 2026, Operating Leases fell 15.81% year-over-year to $5.7 million; the trailing twelve-month figure through Jul 2026 stood at $5.7 million (down 15.81% YoY), and the FY2025 full-year result was $6.5 million, up 352.35% from the prior year.
• Operating Leases was $5.7 million for Q3 2026 at enGene Therapeutics, down from $6.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.7 million in Q3 2025 to a low of $1.3 million in Q1 2025.
• A 3-year average of $3.6 million and a median of $1.6 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases retreated 16.92% in 2025 and soared 367.47% in 2026, its largest moves.
• enGene Therapeutics' Operating Leases stood at $1.4 million in 2024, then soared by 352.35% to $6.5 million in 2025, then dropped by 12.19% to $5.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $5.7 million in Q3 2026, $6.0 million in Q2 2026, and $6.2 million in Q1 2026.